FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the use of recombinant antibodies that specifically bind human proprotein convertase of subtilisin/kexin type 9 (PCSK9); it can be used in medicine for the treatment of patients with a high cardiovascular risk, suffering from hypercholesterinemia and diabetes mellitus type 1 or 2, receiving a therapeutic agent based on insulin.
EFFECT: invention allows for safe and effective reduction in the LDL-C level in patients with diabetes mellitus type 1 or 2 that have a high cardiovascular risk and a high LDL-C level despite the treatment with the maximum tolerated dose of statins.
19 cl, 5 dwg, 16 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING PCSK9 INHIBITOR FOR REDUCING CARDIOVASCULAR RISK | 2019 |
|
RU2837845C2 |
| METHOD OF TREATING DISEASES ASSOCIATED WITH CHOLESTEROL | 2021 |
|
RU2832333C1 |
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS | 2012 |
|
RU2721279C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| ANTAGONISTS | 2019 |
|
RU2839429C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| AGONISTIC ANTIBODY TO LEPTIN RECEPTOR FOR USE IN TREATMENT OF METABOLISM DISORDERS OR HYPOLEPTINEMIA | 2019 |
|
RU2812670C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION | 2017 |
|
RU2772508C2 |
| DOSING STRATEGY REDUCING CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES | 2019 |
|
RU2799529C2 |
